129 related articles for article (PubMed ID: 26388534)
1. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial.
Sutter RW; Bahl S; Deshpande JM; Verma H; Ahmad M; Venugopal P; Rao JV; Agarkhedkar S; Lalwani SK; Kunwar A; Sethi R; Takane M; Mohanty L; Chatterjee A; John TJ; Jafari H; Aylward RB
Lancet; 2015 Dec; 386(10011):2413-21. PubMed ID: 26388534
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.
Bandyopadhyay AS; Gast C; Rivera L; Sáez-Llorens X; Oberste MS; Weldon WC; Modlin J; Clemens R; Costa Clemens SA; Jimeno J; Rüttimann R
Lancet Infect Dis; 2021 Apr; 21(4):559-568. PubMed ID: 33284114
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine.
Xu J; Liu Y; Qiu W; Li W; Hu X; Li X; Fan Q; Tang W; Wang Y; Wang Q; Yao N
BMC Infect Dis; 2024 May; 24(1):535. PubMed ID: 38807038
[TBL] [Abstract][Full Text] [Related]
4. Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.
Lopez-Medina E; Melgar M; Gaensbauer JT; Bandyopadhyay AS; Borate BR; Weldon WC; Rüttimann R; Ward J; Clemens R; Asturias EJ
Vaccine; 2017 Jun; 35(28):3591-3597. PubMed ID: 28455172
[TBL] [Abstract][Full Text] [Related]
5. Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame.
Gaensbauer JT; Gast C; Bandyopadhyay AS; O'Ryan M; Saez-Llorens X; Rivera L; Lopez-Medina E; Melgar M; Weldon WC; Oberste MS; Rüttimann R; Clemens R; Asturias EJ
Clin Infect Dis; 2018 Oct; 67(suppl_1):S57-S65. PubMed ID: 30376095
[TBL] [Abstract][Full Text] [Related]
6. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M
J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179
[TBL] [Abstract][Full Text] [Related]
7. The Immunogenicity of Monovalent Oral Poliovirus Vaccine Type 1 (mOPV1) and Inactivated Poliovirus Vaccine (IPV) in the EPI Schedule of India.
Mohanty L; John TJ; Pawar SD; Ramanan PV; Agarkhedkar S; Haldar P
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675806
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing anti-polio antibody titre in newborn babies in post-polio eradication period in Nigeria.
Ughasoro MD; Nnakenyi I; Echendu N; Akpeh JO; Oji-Onuoha S; Anyaoha U; Mbanefo N; Ofodile K
Vaccine; 2023 Nov; 41(46):6820-6823. PubMed ID: 37806806
[TBL] [Abstract][Full Text] [Related]
9. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.
Voorman A; Lyons H; Bennette C; Kovacs S; Makam JK; F Vertefeuille J; Tallis G
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A85-A92. PubMed ID: 35339308
[TBL] [Abstract][Full Text] [Related]
10. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2018 Apr; 18(1):165. PubMed ID: 29631539
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of experimental stand-alone trivalent, inactivated Sabin-strain polio vaccine formulations in healthy infants: A randomized, observer-blind, controlled phase 1/2 trial.
Cramer JP; Jimeno J; Han HH; Lin S; Hartmann K; Borkowski A; Sáez-Llorens X
Vaccine; 2020 Jul; 38(33):5313-5323. PubMed ID: 32563609
[TBL] [Abstract][Full Text] [Related]
12. Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial.
Sharma AK; Verma H; Estivariz CF; Bajracharaya L; Rai G; Shah G; Sherchand J; Jones KAV; Mainou BA; Chavan S; Jeyaseelan V; Sutter RW; Shrestha LP
Lancet Microbe; 2023 Nov; 4(11):e923-e930. PubMed ID: 37774729
[TBL] [Abstract][Full Text] [Related]
13. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses.
Thompson KM; Kalkowska DA; Duintjer Tebbens RJ
Vaccine; 2015 Mar; 33(13):1568-77. PubMed ID: 25701673
[TBL] [Abstract][Full Text] [Related]
14. Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status.
John TJ; Vashishtha VM
Indian J Med Res; 2013 May; 137(5):881-94. PubMed ID: 23760372
[TBL] [Abstract][Full Text] [Related]
15. Serological survey on immunity status against polioviruses in children and adolescents living in a border region, Apulia (Southern Italy).
Tafuri S; Prato R; Martinelli D; Calvario A; Bozzi A; Labianca M; Patti A; Lopalco PL; Germinario C
BMC Infect Dis; 2008 Oct; 8():150. PubMed ID: 18973678
[TBL] [Abstract][Full Text] [Related]
16. Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
Ochoge M; Futa AC; Umesi A; Affleck L; Kotei L; Daffeh B; Saidy-Jah E; Njie A; Oyadiran O; Edem B; Jallow M; Jallow E; Donkor SA; Tritama E; Abid T; Jones KAV; Mainou BA; Konz JO; Fix A; Gast C; Clarke E
Lancet; 2024 Mar; 403(10432):1164-1175. PubMed ID: 38402887
[TBL] [Abstract][Full Text] [Related]
17. Observational analysis of the immunogenicity and safety of various types of spinal muscular atrophy vaccines.
Sun G; Wang G; Zhong H
Inflammopharmacology; 2024 Apr; 32(2):1025-1038. PubMed ID: 38308795
[TBL] [Abstract][Full Text] [Related]
18. Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.
Eggers M; Terletskaia-Ladwig E; Rabenau HF; Doerr HW; Diedrich S; Enders G; Enders M
BMC Infect Dis; 2010 Dec; 10():347. PubMed ID: 21143885
[TBL] [Abstract][Full Text] [Related]
19. Monitoring and Validation of the Global Replacement of tOPV with bOPV, April-May 2016.
Farrell M; Hampton LM; Shendale S; Menning L; Gonzalez AR; Garon J; Dolan SB; du Châtellier GM; Wanyoike S; Chang Blanc D; Patel MM
J Infect Dis; 2017 Jul; 216(suppl_1):S193-S201. PubMed ID: 28838162
[TBL] [Abstract][Full Text] [Related]
20. Use of inactivated poliovirus vaccine for poliovirus outbreak response.
Bandyopadhyay AS; Lopez Cavestany R; Blake IM; Macklin G; Cooper L; Grassly N; Nery ALMDS; Mach O
Lancet Infect Dis; 2024 May; 24(5):e328-e342. PubMed ID: 38012892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
